Search

Your search keyword '"Umez-Eronini, Amarachi A."' showing total 15 results
Start Over Author "Umez-Eronini, Amarachi A." Search Limiters Available in Library Collection
15 results on '"Umez-Eronini, Amarachi A."'

3. Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial

Author

Udell, Jacob A., Bhatt, Deepak L., Braunwald, Eugene, Cavender, Matthew A., Mosenzon, Ofri, Steg, Ph. Gabriel, Davidson, Jaime A., Nicolau, Jose C., Corbalan, Ramon, Hirshberg, Boaz, Frederich, Robert, Im, KyungAh, Umez-Eronini, Amarachi A., He, Ping, McGuire, Darren K., Leiter, Lawrence A., Raz, Itamar, and Scirica, Benjamin M.

Published
2015
Full Text
View/download PDF

6. Predictors of Long‐term Adherence to Evidence‐based Cardiovascular Disease Medications in Outpatients With Stable Atherothrombotic Disease: Findings From the REACH Registry

Author

Rodriguez, Fátima, Cannon, Christopher P., Steg, Ph. Gabriel, Kumbhani, Dharam J., Goto, Shinya, Smith, Sidney C., Eagle, Kim A., Ohman, E. Magnus, Umez‐Eronini, Amarachi A., Hoffman, Elaine, and Bhatt, Deepak L.

Subjects
Male, Health Knowledge, Attitudes, Practice, Time Factors, Medication Adherence, Residence Characteristics, Risk Factors, Ambulatory Care, Odds Ratio, Secondary Prevention, Humans, Prospective Studies, Registries, Aged, Quality and Outcomes, Chi-Square Distribution, Incidence, Racial Groups, Age Factors, Cardiovascular Agents, Middle Aged, Logistic Models, Treatment Outcome, Cardiovascular Diseases, Multivariate Analysis, Practice Guidelines as Topic, Female, Self Report
Abstract

BACKGROUND: Despite overall improvements in cardiovascular‐disease therapies and outcomes, medication nonadherence remains an important barrier to effective secondary prevention of atherothrombotic disease. HYPOTHESIS: Long‐term medication adherence in outpatients with stable atherothrombotic disease is impacted by demographic and clinical factors. METHODS: We examined data from the prospective international Reduction of Atherothrombosis for Continued Health (REACH) Registry. Analyses were derived from 25 737 patients with established atherothrombotic disease with complete adherence data at enrollment and at year 4. Adherence was defined as patients' self‐report of taking medications based on class I American College of Cardiology/American Heart Association guidelines for secondary prevention as defined, including antiplatelet agents, statins, and antihypertensive medications. RESULTS: Among patients with atherothrombotic disease, 12 500 (48.6%) were deemed adherent to guideline‐recommended medications. Adherent patients were younger, white, and had less polyvascular disease. Hispanic and East Asian patients were less likely to be adherent as compared with white patients (odds ratio [OR]: 0.72, 95% confidence interval [CI]: 0.59‐0.88; and OR: 0.67, 95% CI: 0.53‐0.83, respectively). Patients who had a nonfatal MI or underwent coronary angioplasty/stenting during follow‐up were more likely to be adherent compared with patients without these events (OR: 1.73, 95% CI: 1.25‐2.38; and OR: 2.15, 95% CI: 1.72‐2.67, respectively). On the other hand, nonfatal stroke during follow‐up was inversely associated with adherence (OR: 0.77, 95% CI: 0.61‐0.97). CONCLUSIONS: Using a large international registry of outpatients with atherothrombotic disease, we found that age, region, race/ethnicity, and incident cardiovascular events were predictive of long‐term guideline adherence for secondary prevention, suggesting that certain patient groups may benefit from targeted interventions to improve adherence.

Published
2013

8. Response to Letter Regarding Article, “Heart Failure, Saxagliptin and Diabetes Mellitus: Observations From the SAVOR-TIMI 53 Randomized Trial”

Author

Scirica, Benjamin M., primary, Braunwald, Eugene, additional, Raz, Itamar, additional, Cavender, Matthew A., additional, Morrow, David A., additional, Jarolim, Petr, additional, Udell, Jacob A., additional, Mosenzon, Ofri, additional, Im, KyungAh, additional, Umez-Eronini, Amarachi A., additional, Pollack, Pia S., additional, Hirshberg, Boaz, additional, Frederich, Robert, additional, Lewis, Basil S., additional, McGuire, Darren K., additional, Davidson, Jaime, additional, Steg, Gabriel, additional, and Bhatt, Deepak L., additional

Published
2015
Full Text
View/download PDF

9. Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial

Author

Udell, Jacob A., primary, Bhatt, Deepak L., additional, Braunwald, Eugene, additional, Cavender, Matthew A., additional, Mosenzon, Ofri, additional, Steg, Ph. Gabriel, additional, Davidson, Jaime A., additional, Nicolau, Jose C., additional, Corbalan, Ramon, additional, Hirshberg, Boaz, additional, Frederich, Robert, additional, Im, KyungAh, additional, Umez-Eronini, Amarachi A., additional, He, Ping, additional, McGuire, Darren K., additional, Leiter, Lawrence A., additional, Raz, Itamar, additional, and Scirica, Benjamin M., additional

Published
2014
Full Text
View/download PDF

10. Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial

Author

Scirica, Benjamin M., primary, Braunwald, Eugene, additional, Raz, Itamar, additional, Cavender, Matthew A., additional, Morrow, David A., additional, Jarolim, Petr, additional, Udell, Jacob A., additional, Mosenzon, Ofri, additional, Im, KyungAh, additional, Umez-Eronini, Amarachi A., additional, Pollack, Pia S., additional, Hirshberg, Boaz, additional, Frederich, Robert, additional, Lewis, Basil S., additional, McGuire, Darren K., additional, Davidson, Jaime, additional, Steg, Ph. Gabriel, additional, and Bhatt, Deepak L., additional

Published
2014
Full Text
View/download PDF

11. PROGNOSTIC IMPLICATIONS OF SIMULTANEOUS BIOMARKER ASSESSMENTS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: OBSERVATIONS FROM THE SAVOR-TIMI 53 TRIAL

Author

Scirica, Benjamin, primary, Bhatt, Deepak, additional, Braunwald, Eugene, additional, Raz, Itamar, additional, Steg, Philippe, additional, Davidson, Jaime, additional, Cavender, Matthew, additional, Hirshberg, Boaz, additional, Umez-Eronini, Amarachi, additional, Im, Kelly, additional, Jarolim, Petr, additional, and Morrow, David, additional

Published
2014
Full Text
View/download PDF

15. Predictors of long-term adherence to evidence-based cardiovascular disease medications in outpatients with stable atherothrombotic disease: findings from the REACH Registry.

Author

Rodriguez F, Cannon CP, Steg PG, Kumbhani DJ, Goto S, Smith SC, Eagle KA, Ohman EM, Umez-Eronini AA, Hoffman E, and Bhatt DL

Subjects
Age Factors, Aged, Cardiovascular Diseases diagnosis, Cardiovascular Diseases ethnology, Chi-Square Distribution, Female, Humans, Incidence, Logistic Models, Male, Middle Aged, Multivariate Analysis, Odds Ratio, Practice Guidelines as Topic, Prospective Studies, Racial Groups, Registries, Residence Characteristics, Risk Factors, Secondary Prevention standards, Self Report, Time Factors, Treatment Outcome, Ambulatory Care standards, Cardiovascular Agents therapeutic use, Cardiovascular Diseases drug therapy, Health Knowledge, Attitudes, Practice ethnology, Medication Adherence ethnology, Secondary Prevention methods
Abstract

Background: Despite overall improvements in cardiovascular-disease therapies and outcomes, medication nonadherence remains an important barrier to effective secondary prevention of atherothrombotic disease., Hypothesis: Long-term medication adherence in outpatients with stable atherothrombotic disease is impacted by demographic and clinical factors., Methods: We examined data from the prospective international Reduction of Atherothrombosis for Continued Health (REACH) Registry. Analyses were derived from 25 737 patients with established atherothrombotic disease with complete adherence data at enrollment and at year 4. Adherence was defined as patients' self-report of taking medications based on class I American College of Cardiology/American Heart Association guidelines for secondary prevention as defined, including antiplatelet agents, statins, and antihypertensive medications., Results: Among patients with atherothrombotic disease, 12 500 (48.6%) were deemed adherent to guideline-recommended medications. Adherent patients were younger, white, and had less polyvascular disease. Hispanic and East Asian patients were less likely to be adherent as compared with white patients (odds ratio [OR]: 0.72, 95% confidence interval [CI]: 0.59-0.88; and OR: 0.67, 95% CI: 0.53-0.83, respectively). Patients who had a nonfatal MI or underwent coronary angioplasty/stenting during follow-up were more likely to be adherent compared with patients without these events (OR: 1.73, 95% CI: 1.25-2.38; and OR: 2.15, 95% CI: 1.72-2.67, respectively). On the other hand, nonfatal stroke during follow-up was inversely associated with adherence (OR: 0.77, 95% CI: 0.61-0.97)., Conclusions: Using a large international registry of outpatients with atherothrombotic disease, we found that age, region, race/ethnicity, and incident cardiovascular events were predictive of long-term guideline adherence for secondary prevention, suggesting that certain patient groups may benefit from targeted interventions to improve adherence., (© 2013 Wiley Periodicals, Inc.)

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results